Item 8.01 Other Events.
On January 9, 2023, Aptevo Therapeutics Inc. ("Aptevo" or the "Company")
announced that the Company has filed a provisional patent with the U.S. Patent
and Trademark Office (USPTO) pertaining to an anti-PD-L1 x anti-CD40 compound,
APVO711, with the potential to fight a range of solid malignancies such as head
and neck squamous cell carcinoma, melanoma, and carcinomas of the lung,
gastrointestinal tract and colon. The Company plans to initiate pre-clinical
studies this year.
A copy of the press release is attached hereto as Exhibit 99.1 and is
incorporated by reference herein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press Release dated January 9, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses